| Systematic (IUPAC) name | |
|---|---|
| 3-{6-{[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino}-3-methylpyridin-2-yl}benzoic acid | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | Investigational |
| Identifiers | |
| CAS number | 936727-05-8 |
| ATC code | None |
| PubChem | CID 16678941 |
| Chemical data | |
| Formula | C24H18F2N2O5 |
| Mol. mass | 452.407 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| (what is this?) (verify) |
|
VX-809 is an experimental drug for the treatment of cystic fibrosis. The drug is designed to be effective in patients that have the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), the defective protein that causes the disease. F508del, meaning that the amino acid phenylalanine in position 508 is missing, is found in about 90% of cystic fibrosis patients.[1]